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The development and evaluation of a
computerized decision aid for the
treatment of psychotic disorders
Magda Tasma1,2, Lukas O. Roebroek1,2,6* , Edith J. Liemburg2, Henderikus Knegtering1,2, Philippe A. Delespaul4,5,
Albert Boonstra3, Marte Swart1,2 and Stynke Castelein1,2,6
Abstract
Background: Routinely monitoring of symptoms and medical needs can improve the diagnostics and treatment of
medical problems, including psychiatric. However, several studies show that few clinicians use Routine Outcome
Monitoring (ROM) in their daily work. We describe the development and first evaluation of a ROM based
computerized clinical decision aid, Treatment-E-Assist (TREAT) for the treatment of psychotic disorders. The goal is
to generate personalized treatment recommendations, based on international guidelines combined with outcomes
of mental and physical health acquired through ROM. We present a pilot study aimed to assess the feasibility of
this computerized clinical decision aid in daily clinical practice by evaluating clinicians’ experiences with the system.
Methods: Clinical decision algorithms were developed based on international schizophrenia treatment guidelines
and the input of multidisciplinary expert panels from multiple psychiatric institutes. Yearly obtained diagnostic
(ROM) information of patients was presented to treating clinicians combined with treatment suggestions generated
by the algorithms of TREAT. In this pilot study 6 clinicians and 16 patients of Lentis Psychiatric Institute used the
application. Clinicians were interviewed and asked to fill out self-report questionnaires evaluating their opinions
about ROM and the effectiveness of TREAT.
Results: Six clinicians and 16 patients with psychotic disorders participated in the pilot study. The clinicians were
psychiatrists, physicians and nurse-practitioners which all worked at least 8 years in mental health care of which at
least 3 years treating patients with psychotic illnesses. All Clinicians found TREAT easy to use and would like to
continue using the application. They reported that TREAT offered support in using diagnostic ROM information
when drafting the treatment plans, by creating more awareness of current treatment options.
Conclusion: This article presents a pilot study on the implementation of a computerized clinical decision aid
linking routine outcome monitoring to clinical guidelines in order to generate personalized treatment advice. TREAT
was found to be feasible for daily clinical practice and effective based on this first evaluation by clinicians. However,
adjustments have to be made to the system and algorithms of the application. The ultimate goal is to provide
appropriate evidence based care for patients with severe mental illnesses.
Keywords: Clinical decision aid, Psychotic disorder, Guidelines, Routine outcome monitoring, Optimal treatment,
Treatment recommendations
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Background
Treatment of psychotic disorders
Almost 1 % of the population in the western world will
eventually fulfil the criteria of schizophrenia or a related
severe mental illness [1]. Core symptoms of many people
suffering from psychotic disorders are hallucinations,
delusions, incoherent thoughts, memory problems, loss
of initiative, flat affect, poverty of speech and social
withdrawal [2]. Moreover, patients frequently experience
problems with psychosocial functioning, such as a lack
of daytime activities, social contacts, intimate relation-
ships and a reduced quality of life [3, 4]. They often have
poor physical health and experience medication side
effects that contribute to an early onset of cardiovascular
diseases. Different studies have shown a reduced life
expectancy ranging from 10 up to 28 years [5, 6]. Some
patients manage to recover both in terms of their symp-
toms, as well as in reaching personal and social goals.
However the majority only partially recovers, with recur-
rence of symptoms and enduring personal and social
problems often for the rest of their life. Especially
patients with the most severe symptoms (fulfilling cri-
teria for schizophrenia or schizoaffective disorders) often
need lifetime medical, psychiatric and social care. Rec-
ommended treatment options are described in national
treatment guidelines; in the Netherlands the Multidiscip-
linary Guideline for Schizophrenia is used (which is
largely in line with the NICE guideline) [7]. The Optimal
Treatment Project revealed that 2 years of optimal,
evidence-based treatment led towards a clear trend in
recovery from clinical impairment and social disability of
patients with psychotic disorders [8]. Despite increasing
evidence that pharmacological and psychosocial inter-
ventions are effective in improving clinical symptoms
and patients’ functioning, the availability of treatment
interventions and integration in psychiatric care is often
suboptimal [9]. Also, many patients with psychotic disor-
ders find it difficult to express their needs, show a de-
creased awareness of their symptoms and only partially
understand the different possible treatment options.
Therefore, psychological, medical and social problems
often go undetected or untreated [10]. There is a
challenge to monitor symptoms and unmet care needs
of these patients in order to offer optimal care, espe-
cially in realizing their varying needs in different
domains for many years.
Routine outcome monitoring
Routine outcome monitoring (ROM) is one such way to
monitor symptoms and care needs. ROM can be
described as the use of standardized instruments to sys-
tematically and repeatedly measure different aspects of
patients’ symptoms, health, social functioning and well-
being in order to improve their treatment [11, 12]. For
patients with schizophrenia and related mental health
problems, regular participation in ROM contributes to
systematic evaluation of their varying needs in (mental)
health care over many years. This could offer these
patients relevant treatment options adjusted to actual
needs. However, only few clinicians use ROM data in their
day-to-day work [13, 14]. In the Northern Netherlands, an
extensive ROM screening called the Pharmacotherapy
Monitoring and Outcome Survey (ROM-Phamous), con-
sisting of a large array of instruments [15], has been im-
plemented since 2007. Its main target is to identify needs
of care in psychiatric, medical and social domains in order
to optimize the treatment of patients with psychotic disor-
ders. The data obtained also allows for scientific research.
Although it has been shown that ROM-Phamous success-
fully helps to identify unmet needs, it is still not optimally
used in clinical decision making and in offering recom-
mended evidence-based treatment options to people with
psychotic disorders [16–18].
Treatment E-assist
There is often not just a single best option when making
treatment decisions in healthcare. Different treatment op-
tions may have varying risks and benefits, making it chal-
lenging to offer the optimal option when decisions are
sensitive to personal preference. Clinical decision aids
(CDAs) are evidence-based tools to support decision mak-
ing in healthcare and have been gaining popularity in vari-
ous medical disciplines [19]. A recent meta-analysis shows
CDAs improve patients’ knowledge about available treat-
ment options, facilitate accurate risk perception and
increase their active involvement in the decision making
process [20]. While knowledge about effective mental
health care keeps growing, translation to daily clinical
practice is lagging [21, 22]. CDAs can serve as a guideline
implementation strategy by transferring evidence-based
knowledge to day-to-day patient care. Despite the poten-
tial benefits of CDAs, their use in mental healthcare is
very limited. In one study, a computerized CDA linking
patient specific data to guidelines led to a decrease of
symptoms and lowered re-hospitalization rates among
people with psychotic disorders [23]. However, all diag-
nostic measurements for this CDA had to be collected by
clinicians themselves, making the process time consum-
ing. In the current study we describe Treatment E-Assist
(TREAT). This is a recently developed computerized CDA
that combines diagnostic patient data, collected using
ROM-Phamous, with guidelines. TREAT facilitates the
use of ROM-Phamous in daily clinical practice by
summarising patients’ unmet needs. As a second step,
evidence-based treatment recommendations based on the
Multidisciplinary Guideline for Schizophrenia are gener-
ated to assist the clinician and patient to make shared
decisions about these unmet needs.
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Research aim
This article describes the development of TREAT and the
results of the pilot study, evaluating TREAT, as a comput-
erized CDA designed for the treatment of patients with
psychotic disorders. The pilot study tests the feasibility of
TREAT in daily clinical practice by evaluating clinicians’




The algorithms of TREAT are based on ROM-Phamous
data and the Multidisciplinary Guideline for Schizophre-
nia [7]. The algorithms were designed in collaboration
with two multidisciplinary expert panels, both consisting
of 7 members representing different institutions. These
panels included researchers, psychiatrists, psychologists
and nurse-practitioners, all experienced in working with
ROM-Phamous. The first panel focused on somatic
problems and pharmacotherapy and the second panel
focused on psychosocial interventions. Participants from
the expert panels did not participate in the pilot study
described hereafter.
The first session of the expert panels was an introduc-
tion of the project and a brainstorm to collect first ideas
and thoughts. Next, researchers proposed possible prob-
lematic domains in care for people with a psychotic
disorder: positive symptoms, negative symptoms, cogni-
tive symptoms, psychosocial problems, and somatic
problems. Each domain was further divided into subcat-
egories. The researchers selected matching items from
the ROM-Phamous instruments for each subcategory
and proposed cut-off scores. TREAT displays these sub-
categories as problematic when patient measures on the
matching instruments exceed the cut-off scores. The
draft proposal was then discussed with the panels, until
consensus was reached. Cut-off scores were based on
expert opinions when explicit guidelines were lacking.
Instead of the Multidisciplinary Guideline for Schizo-
phrenia [7], the pharmacotherapy panel decided to use a
more detailed guideline for the treatment of cardiovas-
cular risk factors based on the input of somatic doctors
working in psychiatry (of Mental Health Care Center
Drenthe, The Netherlands). This guideline (Guideline for
Cardiovascular Risk Management Drenthe) offers cut-off
scores and treatment recommendations on cardiovascu-
lar risk factors for patients who have been using anti-
psychotic medication for a long period of time. Finally,
the researchers proposed treatment recommendations to
both panels for each care domain, based on the Multi-
disciplinary Guideline for Schizophrenia [7]. Treatment
recommendations were complemented where necessary
and discussed until consensus was reached. The final
TREAT algorithms were discussed with two guideline
experts (HK and SC) to assess whether the Multidiscip-
linary Guideline for Schizophrenia [7], had been prop-
erly followed. Figure 1 depicts a schematic of TREAT.
Program design
ROM-Phamous and TREAT were both developed by a
company (RoQua) that specializes in privacy protecting
ROM systems that are accessed via the electronic patient
record. TREAT has been built as an addition to the
ROM-Phamous system and generates an interactive
(Dutch) report for each individual patient. The first part
of the report displays a summary of the ROM results. It
contains a graph depicting symptom dimensions, treat-
ment effects, patient satisfaction and unmet needs in
different areas of life, such as mental health, physical
health and antipsychotic medication. It also depicts gen-
eral information about the patient, for instance the types
of treatment the patient has received during the previous
year. Finally, an overview is depicted of all care domains
that are measured by ROM highlighting (in blue) which
areas might (still) be problematic for a patient as
depicted in Fig. 2. When a clinician selects a care do-
main, the relevant instruments, items, scores and treat-
ment recommendations are displayed. In the graphs, the
color of a bar indicates the severity of the problem
(green = no problem, orange = potential problem and
red = problem). On each page that depicts a care do-
main, one can click on the “back to overview” button to
move back to the summary page. Clinicians can navigate
through the TREAT report to assess all relevant
ROM-Phamous results and treatment recommendations
of a patient as depicted in Figs. 2 and 3.
Pilot study
Participants
Six clinicians and sixteen patients of two (outpatient)
Functional Assertive Community Treatment (FACT)
teams of Lentis Psychiatric Institute participated in the
pilot study. The clinicians were three psychiatrists, two
nurse-practitioners and one physician. Patients were
eligible for the study when they had a DSM IV diagnosis
on the psychosis spectrum, or a personality or mood
disorder with psychotic features. All patients filled out
an informed consent form. The procedures were in ac-
cordance with the declaration of Helsinki as confirmed
Fig. 1 Schematic of TREAT
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Fig. 2 Screenshot of TREAT 1
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Fig. 3 Screenshot of TREAT 2
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by the Medical Ethics Committee of the University
Medical Center Groningen.
Procedure
Before the clinicians started using TREAT, they were
asked to fill out a questionnaire that assessed their opin-
ions about ROM-Phamous. Next, each clinician used
TREAT before and/or during the discussion of the ROM
results with a patient. The first three patients with
psychotic disorders scheduled to have an appointment
with their clinician to discuss their yearly ROM results,
were asked to participate in the study. One of the six cli-
nicians only participated with one patient due to plan-
ning issues during the time of this pilot study and
patients declining to participate. The nurse who per-
formed the ROM-Phamous screening was instructed to
create the individual TREAT report. Both the nurses and
the clinicians received instructions about TREAT from a
researcher (MT). During these hour long treatment ses-
sions, ROM results are discussed and treatment plans
are drafted or adjusted. Afterwards, clinicians and pa-
tients filled out a questionnaire about the clinical deci-
sion making process during the sessions. This included
questions about the topics that were discussed and the
treatment options that were considered. At the end of
the pilot study, clinicians filled out a questionnaire and
participated in a brief open interview that both assessed
their experiences with TREAT.
Measures
Assessments were made with two self-developed,
theory-based Dutch questionnaires. The first one was
the ‘ROM State-of-Mind’ consisting of 24 items, with
the first 22 items assessing participants’ acceptance of
ROM-Phamous on a Likert scale from 1 (completely
disagree) to 5 (completely agree). Item 23 assessed over-
all appreciation of ROM-Phamous on a scale from 1
(very poorly) to 10 (excellent) and item 24 was an open
question about suggestions and comments regarding
ROM-Phamous. Items constituted seven subscales, of
which five had a high internal consistency (Cronbach’s
Alpha ≥ .7) and two a low internal consistency (Cron-
bach’s Alpha < .4) [18].
Secondly, participants filled out the ‘TREAT State-of-Mind’
consisting of 27 items assessing statements about
TREAT, each rated on a Likert scale from 1 (com-
pletely disagree) to 5 (completely agree). The items
constituted eight subscales, measuring usage behav-
iour, support, power, issue-impact, emotion, ease of
use, usefulness, and facilitating conditions. The fol-
lowing two items assessed the acceptance of TREAT
in general and the integration of both TREAT and
ROM-Phamous. Both items were rated on a scale
from 1 (very poorly) to 10 (excellent). The next item
was an open question to collect ideas, comments or
suggestions about TREAT.
The questionnaire also registered the amount of times
clinicians consulted TREAT and for how long they had
used TREAT on average per consult. The remaining six
items assessed clinicians’ characteristics: profession,
department, gender, age, and number of years working
in mental health care and psychosis care.
We used the Clinical Decision Making in Routine Care
(CDRC) questionnaire [24], to assess the treatment
sessions. This questionnaire was translated in to Dutch
and expanded with specific categories, largely represent-
ing the problems that are assessed with TREAT (see
Additional file 1). The CDRC has a staff and patient
version, consisting of 22 and 21 items each. The original
authors, CEDAR study group, provided permission to
use the questionnaire.
Results
Clinicians’ experiences with ROM and TREAT
All clinicians had worked with ROM-Phamous for
7 years on average (ranging from 3 years to 9 years).
They were generally positive about ROM-Phamous,
grading it with an average of 7 (SD 0.89) on a scale from
1 (poor) to 10 (excellent). They have positive feelings
towards ROM-Phamous (subscale ‘emotion’), see it as a
useful addition to their job (subscale ‘usefulness’), but
don’t find it very easy to use (subscale ‘ease of use’).
Results are depicted in Table 1. Clinicians were also
positive about TREAT with an average rating of 7.5 (SD
0.84) and the integration of TREAT and ROM with an
average rating of 7.3 (SD 1.37) on a scale from 1 (poor)
to 10 (excellent). Most clinicians had used TREAT at
least three times during the pilot study, with the excep-
tion of one clinician who only worked with TREAT a sin-
gle time. The time TREAT was used differed per user: 5 to
15 min (1 psychiatrist), 15 to 30 min (1 nurse-practitioner
and 1 physician) and more than 30 min per session (2
psychiatrist and 1 nurse-practitioner). Most clinicians find
TREAT useful and expect it will help them improve their
work. They state that it helps to interpret the (diagnosti-
cal) ROM-Phamous results and offers support in drafting
the treatment plan. It also enhances awareness of the
existing treatment options (subscale ‘usefulness’). TREAT
fits with good clinical care, clinicians are proud of its de-
velopment (subscale ‘emotion’) and expect to use TREAT
in the future (subscale ‘usage behaviour’). TREAT is
thought to be easy to use and requires little mental effort.
Opinions about the lay-out of TREAT are mixed (subscale
‘ease of use’), for example some clinicians preferred the
graphs displaying data vertically whilst others preferred it
horizontally. Most clinicians state that they have enough
time to use TREAT in daily clinical practice and that it
helps them to work more efficiently (subscale ‘facilitating
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conditions’). They do not think TREAT will have impact
on their professional autonomy (subscale ‘power’), on
their job or on patient care in general (subscale ‘issue-im-
pact’). Results are depicted in Table 2. Some clinicians pre-
ferred to use TREAT on the computer while others
preferred to print the information. The topics that were
mentioned in the open interview are depicted in Table 3.
Feasibility of questionnaires
Both clinicians and patients completed the CDRC ques-
tionnaires. All clinicians filled out the staff version of the
CDRC but some of the patients experienced difficulties
with their version of the questionnaire. They remem-
bered most of the topics discussed in the feedback
sessions but some had trouble to be specific or to
categorize the different topics or mention specific treat-
ment options that were suggested.
Discussion
A ROM inventory in 2011, for the Dutch ministry of
health, welfare and sport, recommended combining
ROM to CDAs to improve the treatment process within
mental healthcare [25]. Despite these recommendations
such systems are currently unavailable. With TREAT, a
computerized CDA has been developed linking ROM to
treatment guidelines. In this way TREAT generates per-
sonalized treatment advice for the treatment of patients
with psychotic disorders. The primary aim of this pilot
study was to describe the development of TREAT and
assess its feasibility for daily clinical practice.
Clinicians’ evaluations
In general clinicians were positive about working with
TREAT. Most of them found the system easy to use
without requiring extra mental effort or time. This is
important as usability and limited time investment are
the two most important factors affecting successful
implementation of CDAs [26]. One clinician did prefer
the printed TREAT report for the feedback sessions
because this person felt that the computer could disturb
communication with patients. However, concerns from a
previous study that computer use would be distracting,
decrease eye contact or depersonalize the interaction
[27], were not replicated. All clinicians indicated they
would like to continue working with TREAT as they
found it fitting with good clinical practice. Some
Table 1 Scores on the ROM State-of-Mind questionnaire (clinicians)
Subscale Items Mean Score (SD)
Acceptance 2. I use ROM-Phamous results in the treatment of my patients. 4,00 (0,63)
22. I actively use the information offered by ROM-Phamous. 3,00 (0,63)
Support 1. I express my concerns about ROM. 3,00 (1,27)
21. I tell people that it’s good that ROM-Phamous exists. 3,50 (1,52)
Power 13. I experience ROM-Phamous as a form of behavioural control. 1,67 (0,52)
18. Because of ROM-Phamous I have more control over my job. 2,83 (0,75)
Emotion 5. Use of ROM-Phamous fits with my professional values and beliefs. 4,00 (0,89)
6. Use of ROM-Phamous fits with good clinical care. 4,67 (0,52)
7. I am proud that ROM-Phamous is used in my institution. 3,67 (0,82)
8. I am worried about the existence of ROM-Phamous. 2,17 (1,47)
Ease of use 3. ROM-Phamous results are easy to interpret. 3,00 (0,89)
9. ROM-Phamous is easy to use. 2,83 (0,75)
10. Working with ROM-Phamous requires little (extra) mental effort. 2,67 (0,82)
Usefulness 4. ROM-Phamous adds value to the treatment of my patients. 4,33 (0,52)
11. Because of ROM-Phamous I am better able to perform my job. 3,67 (0,82)
12. Because of ROM-Phamous I am better supported in my job. 4,17 (0,75)
15. The instruments of the ROM-Phamous protocol provide me with enough
valuable information about my patients.
3,83 (0,41)
16. ROM-Phamous identifies care needs. 4,00 (0,63)
17. Because of ROM-Phamous more thought goes into care modules. 3,50 (0,55)
Facilitating conditions 14. I have enough time to use ROM-Phamous in my daily work. 2,00 (0,63)
19. Because of ROM-Phamous I am able to work more efficiently. 3,50 (0,55)
20. Using ROM-Phamous costs extra time. 3,50 (0,84)
1 = completely disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = completely agree, − = no opinion
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concerns were expressed about the recommendations
being or becoming too familiar over time. Lack of nov-
elty could potentially stop clinicians from working with
the application. In contrast, some clinicians became
more aware of guidelines and discovered new treatment
options. There is growing evidence that treatment in
accordance with guidelines within mental healthcare,
can positively affect patient care [8, 28, 29]. One clin-
ician suggested that the ROM-Phamous results of previ-
ous years should be incorporated in order to evaluate
changes over time. This exemplifies that the TREAT
algorithms can be improved and tailored even more to
individual patients. CDAs sometimes fail to take
contextual information into account or have algorithms
that insufficiently fit complex patient scenarios [30].
When asking clinicians about their opinions regarding
ROM-Phamous, they indicated that the outcomes are
not always easy to use for clinical decision making. This
is in line with previous studies showing that the
outcomes of ROM-Phamous are not used to its full
potential in daily clinical practice [17, 18, 31]. TREAT
simplifies the interpretation of these outcomes and facil-
itates a basis for more explicit decision making. Future
research should focus on the effects of TREAT in the
clinical decision making process. Lessons learned can
improve the TREAT application, but may also help to
develop other CDA’s.
Future adjustments & research
Adequately informing patients about their health and
available treatment options is the future of healthcare, in
which CDAs should play a pivotal role. While CDAs are
commonly used in medical fields such as oncology, or-
thopedics and cardiology, its use in mental healthcare is
still very rare. With TREAT a high quality and easy to
use CDA is now available in this field. Some adjustments
Table 2 Scores on the TREAT State-of-Mind questionnaire (clinicians)
Subscale Items Mean Score (SD)
Usage behaviour 2. If it is up to me, I will start using TREAT as soon as possible. 4,17 (1,60)
3. When TREAT becomes available I will actively use it. 4,83 (0,41)
Support 1. I express my concerns about TREAT. 3,00 (2,19)
26. I will tell people it is good TREAT has been developed. 3,33 (1,86)
Power 4. Because of TREAT I expect to have more influence on the way I do my job. 3,50 (0,55)
5. Because of TREAT I expect to become more dependent on others. 1,83 (0,41)
18. I experience TREAT as a form of behavioural control. 1,50 (0,84)
Issue-impact 6. My job will remain about the same with TREAT. 3,33 (1,21)
7. I expect TREAT to have much influence on the way I do my job. 3,00 (0,89)
8. I expect TREAT to have much influence on the way most clinicians of the
psychosis department do their job.
3,17 (1,17)
9. I expect TREAT to have much influence on patientcare in the psychosis department. 3,50 (1,52)
Emotion 10. Use of TREAT fits with my professional values and beliefs. 3,67 (0,82)
11. Use of TREAT fits with providing good clinical care. 4,33 (0,52)
12. I am proud of the fact that TREAT has been developed and is being investigated. 4,17 (0,98)
13. I am worried about the introduction of TREAT. 2,00 (1,10)
Ease of use 14. TREAT is easy to use. 4,33 (0,82)
15. Working with TREAT requires little (extra) mental effort. 4,33 (0,52)
20. The lay-out / arrangement of TREAT appeals to me. 3,17 (1,47)
Usefulness 16. I expect to be able to better perform my job, because of TREAT. 4,42 (0,66)
17. I expect to receive more support in my job, because of TREAT. 3,67 (1,03)
21. TREAT helps with the interpretation of the ROM-Phamous outcome. 4,33 (0,82)
22. I expect TREAT to offer support in drafting the treatment plan. 4,17 (1,17)
23. Because of TREAT I am more aware of the different treatment options that are available. 3,92 (0,67)
27. Because of TREAT I am more aware of the purpose of ROM-Phamous. 2,67 (1,21)
Facilitating conditions 19. I expect to have enough time to use TREAT in my daily work. 4,00 (1,10)
24. Because of TREAT I can work more efficiently. 4,08 (0,49)
25. Using TREAT costs extra time. 2,33 (1,03)
1 = completely disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = completely agree, − = no opinion
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will be made to the system based on the results of this
pilot study. For instance the algorithms will be updated
to ensure that TREAT reports can still be generated
when part of the data is missing. ROM-Phamous con-
sists of multiple instruments so patients are not always
able to complete all questionnaires. Furthermore, two
printable versions of the TREAT report will be added,
namely a summary and the complete report. These
adjustments will enable a large follow-up study aiming
to investigate the effects of TREAT on clinical decision
making. Because there are hardly any validated method-
ologies available to assess the content of treatment
sessions in mental healthcare, modified and translated
versions of the CDRC questionnaires were tested. Clini-
cians were able to fill out their version. However,
patients experienced difficulties in categorizing the dif-
ferent topics that were discussed during the treatment
sessions. These difficulties probably reflect cognitive dif-
ficulties in line with their psychiatric problems. There-
fore, we will use only the staff version of the CDRC
questionnaire for future research. Clinicians reported
that patients appreciated the TREAT report and that it
could improve shared decision making. Previous
research in somatic medicine supports the notion that
CDAs are effective in improving shared decision-making
[20]. Recently there have been calls for widespread
access to CDAs to improve the level of shared
decision-making within mental healthcare [32]. Patients
prefer an active role in the decision-making process and
are more likely to adhere to their treatment plans if they
actively participated in the draft [33]. The follow-up
study is designed to assess whether CDA’s, in this case
TREAT, can indeed increase shared decision making
within a mental healthcare setting. So far research on
computerized CDAs shows that they may improve dis-
ease management and diagnostics, however the effects
on patients’ functioning and final clinical outcome re-
mains unclear [34]. Assessing the effects of TREAT on
patients’ symptoms, physical health and psychosocial
functioning, will be another important goal of the
follow-up study. If a CDA like TREAT is beneficial in
treatment of psychotic disorders, it might be worthwhile
to develop similar systems for different patient groups.
Strengths and limitations
To the best of our knowledge, this study presents the
first computerized CDA combining ROM and treatment
guidelines in an electronic patient record within mental
health care. TREAT was developed in close collaboration
with healthcare professionals. This is a strength of
TREAT, as sufficient knowledge of developers about the
target group of CDAs is important for successful imple-
mentation [26]. ROM is sometimes experienced as
behavioural control by some users who feel obliged by
political or financial motives [18]. This was not repli-
cated in previous or the current study [17, 18], as all cli-
nicians had positive opinions about ROM-Phamous. A
limitation of the current study is the small sample of
only six clinicians from the same psychiatric institute.
Although large enough to test the applicability of
TREAT in daily clinical practice, a larger sample of clini-
cians from multiple centres are preferred when testing
the effects of the application on the clinical decision
making process and patient outcomes.
Table 3 Topics mentioned in the brief open interview about TREAT (clinicians)
Positive feedback Negative feedback
TREAT improved the efficiency of the treatment session. 5 The treatment recommendations were sometimes repetitive, when
patients had already received certain treatment options in the past. 1,3
TREAT was a good reminder to talk about certain topics,
which otherwise might be forgotten. 3,5
The specific diagnosis of the patient was not mentioned in TREAT. 3
The visual feedback was experienced as pleasant. 3 The treatment recommendations did not add much, new information. It
was however convenient to explicitly go through the different options. 4
The visualizations were especially useful for the patient and
it led to more shared-decision making. 1
The cut-off scores for the somatic parameters in TREAT were different
than the cut-off scores the general practitioner uses. This is confusing. 2
Because of TREAT the discussion of the ROM results became
a more explicit moment to make decisions. 1
The print version of TREAT was too long. The graphs take up much space. 2
When the treatment guidelines change, TREAT needs to be
updated. The maintenance of TREAT is important. 2
The information the ROM nurse added to the ROM results did not appear
in TREAT. Because of this, important information was sometimes missing. 2
ROM-Phamous was confusing and TREAT has made this better
and clearer. 6
It is a risk that clinicians will only follow TREAT and forget about other
potential problems. 5
Certain treatment options in the recommendations were new
and I would not have thought of these options without TREAT.
An example was ‘peer support groups’. 6
It would be helpful if TREAT could also lead to a template for a
treatment plan. 5
The treatment session was more structured and I had the feeling
we had discussed all the important issues, because of TREAT. 5
It would be nice to be able to compare ROM results of previous
years with current results. 1
Clinician identifier: 1, 2, 3, 4, 5 & 6
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Conclusions
This pilot study describes the development and first
evaluation of a computerized CDA (TREAT) linking
ROM to clinical guidelines to generate personalized
treatment recommendations in the treatment of psych-
otic disorders. The primary aim was to assess the feasi-
bility of TREAT for daily clinical practice by evaluating
clinicians’ opinions when working with the system. In
sum, clinicians found TREAT useful for daily clinical
practice, easy to use, fitting with good clinical care and
all of them would like to use the system in the future.
TREAT was not felt to reduce clinicians’ professional
autonomy nor was it perceived as behavioural control.
Clinicians expect TREAT to have a positive impact on
their daily job but are unsure if it will improve patient
outcomes, such as reduced symptoms and improved
psychosocial wellbeing. The application will be adjusted
and improved for a follow-up study based on the results
from this pilot. The follow-up study will investigate the
effects of TREAT on shared decision-making, the clin-
ical decision-making process and patient outcomes.
Additional file
Additional file 1: Clinical decision making in daily care - Staff version.
(DOCX 41 kb)
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